Tagged Articles

metformin 30 articles

Diabetes treatment linked to increased risk of pneumonia

Patients using type 2 diabetes drugs known as thiazolidinediones, such as Actos and Avandia, in combination with the first-line treatment metformin, may be at an increased risk for developing community-acquired pneumonia, according to a new study published in the British Journal of Clinical Pharmacology. The study pitted the drug combination against sulfonylurea with metformin. Sulfonylurea drugs include the brands Diabinese, Amaryl, and Glucotrol. For the study, researchers identified 1,803 cases of community-acquired pneumonia, or CAP, in a cohort of type 2 diabetes patients. Researchers found that patients taking thiazolidinediones with metformin were more likely to develop CAP. There was no significant ... Read More

FDA reverses opinion on metformin in patients with kidney impairment

The widely used, first-line type 2 diabetes drug Metformin can safely be used in patients with mild to moderate kidney impairment, the Food and Drug Administration (FDA) said in a Safety Communication following a review of studies published in medical journals. The drug previously had been strongly discouraged in some patients whose kidneys did not function properly because they were at an increased risk of developing a serious and potentially deadly condition called lactic acidosis, in which too much acid builds up in the blood. The FDA has approved updates to the safety label of Metformin to include this change in ... Read More

European Union approves new combination treatment for type 2 diabetes

European Union drug regulators have approved a new combination pill to treat type 2 diabetes. Vokanamet combines the new diabetes drug Invokana with the standard treatment metformin. The new treatment is made by Johnson & Johnson and will be marketed in Europe by Janssen-Cliag International. The active ingredient in Invokana is canagliflozin, which is in a class of diabetes medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. These drugs are designed to help reduce blood sugar levels by preventing the reabsorption of glucose from the kidneys back into the blood, and allows glucose to be excreted in the urine. The U.S. ... Read More

Europe approves new combination diabetes treatment despite bladder cancer concerns

European drug regulators have approved AstraZeneca and Bristol-Myers Squibb’s combination type 2 diabetes drug Xigduo, making it the first treatment to combine a SGLT2 inhibitor with metformin. Xigduo is a combination of the widely used diabetes drug metformin and dapagliflozin, a new diabetes treatment sold in Europe as Forxiga. It was approved earlier this month by the U.S. Food and Drug Administration (FDA) under the name Farxiga. Dapagliflozin is in a new class of diabetes drugs known as SGLT2 inhibitors. Johnson & Johnson’s SGLT2 Invokana was approved in the U.S. in 2013. Other SGLT2 drugs are currently in development. The ... Read More

FDA requests more data on diabetes drug candidate combining Invokana with metformin

The Food and Drug Administration (FDA) wants more clinical trial data on Janssen’s new type 2 diabetes treatment that combines the recently approved Invokana (canagliflozin) with the widely used metformin, before it will decide whether to approve the new combination therapy. The agency requested more information comparing the twice-daily combination pill with the once-daily canagliflozin. Janssen, a Johnson & Johnson company, says it has the data the agency needs from its comprehensive Phase 3 clinical development program for the drug. Canagliflozin was approved by the FDA in March 2013. It is the first approved drug in a new class of ... Read More

Studies look at cancer risk, prevention with type 2 diabetes medications

A type of diabetes medications known as insulin sensitizers may reduce the risk of cancer by a third in women who used the drugs, a new study suggests. Insulin sensitizers include the commonly prescribed drug metformin as well as Avandia, known generically as rosiglitazone, and Actos, known generically as pioglitazone. The new study claims these insulin sensitizers were better at preventing cancer in women than diabetes drugs known as insulin secretagogues such as glyburide, glipizide and glimepiride. Type 2 diabetics are already 30 to 50 times more likely to develop cancer than those without the metabolic disorder. Women with diabetes ... Read More

New type of metformin for type 2 diabetes fares well in clinical trials

Elcelyx Therapeutics, a “virtual” biotech firm, is hoping positive clinical trial results with its type 2 diabetes drug NewMet will secure the product’s sale to a larger drug company. NewMet is a delayed-release version of metformin, a widely prescribed drug to treat type 2 diabetes. Metformin is not recommended for patients with kidney problems because it can cause a life threatening condition called lactic acidosis. NewMet, however, is designed especially for patients with compromised kidney function. Many diabetics with kidney problems cannot eliminate metformin efficiently, which causes excess metformin to build up in the blood, leading to lactic acidosis. NewMet ... Read More

New diabetes drug controls blood sugar better than other widely prescribed treatments

A new, once-weekly injection for the treatment of type 2 diabetes controls blood sugar levels better than three other widely prescribed diabetes drugs, late-stage clinical trials show. The drug, dulaglutide, made by Eli Lily and Co., was pitted against the long-used insulin drug metformin, and newer type 2 medications Byetta, made by Bristol-Myers Squibb, and Januvia, made by Merck & Co. Januvia is one of the leaders in diabetes treatment with sales topping $4 billion a year. Dulaglutide performed better at lowering blood sugar levels compared to metformin, Byetta and Januvia. Patients on dulaglutide also lost twice as much weight ... Read More

Newly approved type 2 diabetes drugs come with warnings, requirements

After more than five years of reviews and rejections, the dipeptidyl peptidase IV (DDP-4) inhibitor alogliptin has finally been approved by the Food and Drug Administration (FDA). The new drug was approved in three versions to improve blood sugar control in adults with type 2 diabetes. Nesina contains alogliptin as a single-agent drug; Kazano contains alogliptin with metformin; and Oseni contains alogliptin with pioglitazone. The drugs are to be prescribed in combination with diet and exercise. Alogliptin is the fourth DDP-4 inhibitor to gain FDA clearance. Others include sitagliptin, sold under the brand name Januvia; saxagliptin, sold as Onglyza; and ... Read More

AAP issues first-ever guidelines for type 2 diabetes in children, teens

The American Academy of Pediatrics (AAP) has issued the first guidelines for the management of type 2 diabetes in children and teenagers aged 10 to 18. The guidelines were developed to assist pediatricians and pediatric endocrinologists, who most often are used to dealing with type 1 diabetes. However, the increase in childhood obesity has led to more children being diagnosed with type 2 diabetes – a condition once thought to affect adults only. Now, as many as one in three children diagnosed with diabetes has type 2. It can be difficult to quickly distinguish between type 1 and type 2 diabetes in ... Read More